Barclays lowered the firm’s price target on Universal Health (UHS) to $238 from $268 and keeps an Overweight rating on the shares following the Q1 report. The firm says that after accounting for a $30M headwind related to weather and a $15M Affordable Care Act headwind, Universal Health’s organic EBITDA growth decelerated to negative 4% in the quarter.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Universal Health reports Q1 EPS $5.62, consensus $5.46
- Universal Health options imply 5.8% move in share price post-earnings
- UHS Earnings this Week: How Will it Perform?
- Universal Health Expands Credit Facilities for Acquisition Financing
- UHS: Short-Term Operational Headwinds but Intact Long-Term Earnings Power Support Buy Rating and $245 Target